Expression of p21 in Urothelial Carcinoma
Author Information
Author(s): S Clasen, WA Schulz, C-D Gerharz, M-O Grimm, F Christophl, BJ Schmitz-Drager
Primary Institution: Heinrich-Heine-Universität
Hypothesis
The study investigates the expression of the cyclin-dependent kinase inhibitor WAF1/p21 in urothelial carcinoma and its association with tumor grade and stage.
Conclusion
The expression of p21 is frequently observed in low-grade, superficial urothelial carcinomas but is less common in muscle-invasive tumors.
Supporting Evidence
- p21 expression was detected in 66% of pTa tumors and 47% of carcinomata in situ.
- Statistical analysis showed significant differences in p21 expression between low-stage and muscle-invasive tumors.
- Accumulation of p53 protein increased with tumor grade, while p21 expression was associated with lower grades.
Takeaway
This study found that a protein called p21 is often present in early-stage bladder cancers but not in more advanced ones.
Methodology
The study used immunohistochemistry and quantitative RT-PCR to analyze p21 expression in tumor samples.
Limitations
The study did not evaluate mutations in the WAF1/p21 gene in all tumors, and the sample size for RNA analysis was limited.
Participant Demographics
Patients treated for primary or recurrent bladder tumors at Heinrich-Heine University.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website